Cardiac Manifestations in a Group of Romanian Patients with Gaucher Disease Type 1 (a Monocentric Study)

被引:2
|
作者
Lazea, Cecilia [1 ]
Bucerzan, Simona [1 ,2 ]
Al-Khzouz, Camelia [1 ,2 ]
Zimmermann, Anca [3 ]
Vesa, Stefan Cristian [4 ]
Nascu, Ioana [5 ]
Cret, Victoria [5 ]
Crisan, Mirela [5 ]
Asavoaie, Carmen [5 ]
Miclea, Diana [6 ]
Grigorescu-Sido, Paula [7 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Emergency Pediat Hosp, Mother & Child Dept, Pediat Discipline 1,Clin Pediat 1, Cluj Napoca 400370, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Emergency Pediat Hosp, Dept Genet Dis, Cluj Napoca 400370, Romania
[3] Univ Med Ctr, Dept Diabetol & Endocrinol, Clin & Polyclin Internal Med 1, Med Clin 2,Clin Worms, D-55131 Mainz, Germany
[4] Iuliu Hatieganu Univ Med & Pharm, Dept Pharmacol Toxicol & Clin Pharmacol, Cluj Napoca 400012, Romania
[5] Emergency Pediat Hosp, Cluj Napoca 400370, Romania
[6] Iuliu Hatieganu Univ Med & Pharm Emergency Pedia, Dept Med Genet, Cluj Napoca 400012, Romania
[7] Iuliu Hatieganu Univ Med & Pharm, Fac Med, Cluj Napoca 400012, Romania
关键词
Gaucher disease; pulmonary hypertension; valvular heart disease; VENTRICULAR SYSTOLIC DYSFUNCTION; EXPERT CONSENSUS DOCUMENT; PULMONARY-ARTERY PRESSURE; EUROPEAN ASSOCIATION; ECHOCARDIOGRAPHIC-ASSESSMENT; MITRAL REGURGITATION; AMERICAN SOCIETY; RIGHT HEART; HYPERTENSION; CALCIFICATION;
D O I
10.3390/diagnostics11060989
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Gaucher disease (GD), one of the most common lysosomal disorders, is characterised by clinical heterogeneity. Cardiac involvement is rare and refers to pulmonary hypertension (PH), valvular abnormalities and myocardial infiltrative damage. The aim of this study was to evaluate cardiac involvement in a group of Romanian GD patients. Phenotypic and genotypic characterisation was carried out in 69 patients with GD type 1. Annual echocardiography and electrocardiography were performed to assess pulmonary pressure, morphology and function of the valves and electrocardiographic changes. Nine patients (13%) exhibited baseline echocardiographic signs suggesting PH. Mitral regurgitation was present in 33 patients (48%) and aortic regurgitation in 11 patients (16%). One patient presented aortic stenosis. Significant valvular dysfunction was diagnosed in 10% of patients. PH was associated with greater age (p < 0.001), longer time since splenectomy (p = 0.045) and longer time between clinical onset and the start of enzyme replacing therapy (p < 0.001). Electrocardiographic changes were present in five patients (7%).
引用
收藏
页数:19
相关论文
共 50 条
  • [41] A comprehensive monocentric ophthalmic study with Gaucher disease type 3 patients: vitreoretinal lesions, retinal atrophy and characterization of abnormal saccades
    Hopf, Susanne
    Pfeiffer, Norbert
    Liesenfeld, Matthias
    Mengel, Karl-Eugen
    Hennermann, Julia B.
    Schmidtmann, Irene
    Pitz, Susanne
    ORPHANET JOURNAL OF RARE DISEASES, 2019, 14 (01)
  • [42] Skeletal manifestations of children with Gaucher disease type I and type III
    Yuce, Aysel
    Hizarcioglu-Gulsen, Hayriye
    Demir, Hulya
    Emre, Serap Dokmeci
    Gurakan, Figen
    MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S128 - S128
  • [43] Long-term effects of eliglustat on skeletal manifestations in clinical trials of patients with Gaucher disease type 1
    Cox, Timothy M.
    Charrow, Joel
    Lukina, Elena
    Mistry, Pramod K.
    Foster, Meredith C.
    Peterschmitt, M. Judith
    GENETICS IN MEDICINE, 2023, 25 (02)
  • [44] Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience
    Sido, P. Grigorescu
    Drugan, C.
    Cret, V.
    Al-Kzouz, C.
    Denes, C.
    Coldea, C.
    Zimmermann, A.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2007, 30 (05) : 783 - 789
  • [45] Prevalence of kyphosis in patients with Type 1 and Type 3 Gaucher disease
    Vellodi, A.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2010, 48 : S24 - S25
  • [46] A prospective study of neurological manifestations and other comorbidities in adult type I Gaucher disease
    Hollak, C. E. M.
    Marodi, L.
    Biegstraaten, M.
    Van Schaik, I. N.
    Niederau, C.
    Hughes, D.
    Giraldo, P.
    Beck, M.
    MOLECULAR GENETICS AND METABOLISM, 2007, 92 (04) : S22 - S22
  • [47] Long-term bone outcomes in Italian patients with Gaucher disease type 1 or type 3 treated with imiglucerase: A sub-study from the International Collaborative Gaucher Group (ICGG) Gaucher Registry
    Cappellini, Maria Domenica
    Carubbi, Francesca
    Di Rocco, Maja
    Giona, Fiorina
    Giuffrida, Gaetano
    BLOOD CELLS MOLECULES AND DISEASES, 2023, 98
  • [48] Management goals for type 1 Gaucher disease: An expert consensus document from the European working group on Gaucher disease
    Biegstraaten, M.
    Cox, T. M.
    Belmatoug, N.
    Berger, M. G.
    Collin-Histed, T.
    Vom Dahl, S.
    Di Rocco, M.
    Fraga, C.
    Giona, F.
    Giraldo, P.
    Hasanhodzic, M.
    Hughes, D. A.
    Iversen, P. O.
    Kiewiet, A. I.
    Lukina, E.
    Machaczka, M.
    Marinakis, T.
    Mengel, E.
    Pastores, G. M.
    Ploeckinger, U.
    Rosenbaum, H.
    Serratrice, C.
    Symeonidis, A.
    Szer, J.
    Timmerman, J.
    Tylki-Szymanska, A.
    Hubshman, M. Weisz
    Zafeiriou, D. I.
    Zimran, A. a
    Hollak, C. E. M.
    BLOOD CELLS MOLECULES AND DISEASES, 2018, 68 : 203 - 208
  • [49] Improvement of bone disease by imiglucerase (Cerezyme) therapy in patients with skeletal manifestations of type 1 Gaucher disease: results of a 48-month longitudinal cohort study
    Sims, K. B.
    Pastores, G. M.
    Weinreb, N. J.
    Barranger, J.
    Rosenbloom, B. E.
    Packman, S.
    Kaplan, P.
    Mankin, H.
    Xavier, R.
    Angell, J.
    Fitzpatrick, M. A.
    Rosenthal, D.
    CLINICAL GENETICS, 2008, 73 (05) : 430 - 440
  • [50] Bone marker alterations in patients with type 1 Gaucher disease
    Ciana, G
    Martini, C
    Leopaldi, A
    Tamaro, G
    Katouzian, F
    Ronfani, L
    Bembi, B
    CALCIFIED TISSUE INTERNATIONAL, 2003, 72 (03) : 185 - 189